Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here.
Questions
1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05)
2. What is likely to be the next major breakthrough in this area? (1:25)
Ibrahim El Houssieny has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
